A response to: BAK1 gene variation and abdominal aortic aneurysms—results may have been prematurely overrated. Questions of sequence fidelity, intraorganismal genetic heterogeneity, the nature of pseudogenes, and RNA editing by Gottlieb, Bruce et al.
Human Mutation LETTER TO THE EDITORS
A Response to: BAK1 Gene Variation and Abdominal
Aortic Aneurysms—Results May Have Been
Prematurely Overrated. Questions of Sequence
Fidelity, Intraorganismal Genetic Heterogeneity,
the Nature of Pseudogenes, and RNA Editing
Bruce Gottlieb,
1,2 Lorraine E. Chalifour,
1,3 and Morris Schweitzer
1,4
1Lady Davis Institute for Medical Research, Jewish General Hospital, Montre ´al, Que ´bec, Canada;
2Department of Human Genetics;
3Division of
Experimental Medicine, Department of Medicine, McGill University, Montre ´al, Que ´bec, Canada;
4Department of Endocrinology, Jewish General
Hospital, Montre ´al, Que ´bec, Canada
Communicated by Garry R. Cutting
Received 14 April 2010; accepted revised manuscript 8 July 2010.
Published online 28 September 2010 in Wiley Online Library (wileyonlinelibrary.com). DOI 10.1002/humu.21323
We thank Ku ¨ry et al. [2010] for their letter. They raise a
number of issues with regard to our initial article that reported on
variations in BAK1 gene (MIM] 600516) sequence expressed in
the abdominal aorta (AA) tissue when compared with leukocyte
genomic DNA sequence [Gottlieb et al., 2009]. In a subsequent
letter [Gottlieb et al., 2010], we noted that when we compared the
genomic BAK1 sequence in matching blood and tissue samples,
the blood and tissue BAK1 genomic sequences were identical to
the reference BAK1 genomic sequence, which primarily suggested
that an unusual form of RNA editing could possible be involved.
Ku ¨ry et al. [2010] have raised three issues with regard to
possible explanations for our results.
1. That the BAK1 sequence variants are due to somatic events,
which they dismiss as highly unlikely. We agree with them that
this is unlikely, for the simple reason that the genomic DNA
appears to be similar, which is the reason that we did not
comment on this earlier.
2. That differences between DNA and RNA sequences must lie at
the RNA level, which they dismiss as impossible because the
form of RNA editing that we observed except for C4T
(c.454C4T) had not been reported. However, both G4A
(c.336G4A) and T4C (c.366T4C) have now been reported
in the TPH2 gene isolated from human amygdala samples
[Grohmann et al., 2010]. Although the exact mechanism has
yet to be elucidated it seems somewhat premature to dismiss
the validity of this being due to RNA editing just because no
possible mechanism has yet been discovered.
3. They again raise the possibility that that the sequence variants
that we report are due to a Bcl-2-like 7 pseudogene 1, alias
BAK2 with gene ID number 600, NC_000020.10, the so-called
BAK2 pseudogene, being sequenced. We have already
described in detail the techniques and safeguards that we have
used to ensure that BAK2 was not sequenced in our response
[Gottlieb et al., 2010] to a previous letter [Hatchwell, 2010].
It is clear that the BAK1 sequence we amplified from the cDNA
prepared from our DNAase treated RNA (not, of course, RNAase
treated, as mistakenly noted by Ku ¨ry et al. [2010]) resembles both
BAK1 and BAK2 yet copies neither exactly. At amino acid 2 the
chromosome 20 BAK2 reference sequence of NC_000020.10 has
the sequence ATG/GCC/TCG. In contrast, BAK1 mRNA
(NM_001188), and all our samples isolated from AAA and all
AA cDNA samples have the sequence ATG/GCT/TCG (Table 1). In
Figure 2, Ku ¨ry et al. [2010] reference five other BAK2 sequences to
indicate that there is heterogeneity at nucleotide 217. The results,
however, are likely from only three different isolates not five.
BAK2 chromosome 20 sequences NC_000020.10 and NT_011362
contain ATG/GCC/TCG, with both sequences having the same
citation [Deloukas et al., 2001], suggesting that they are from the
same isolate. BAK2 chromosome 20 sequence NG_000850.5 has
ATG/GCT/TCG and is referenced in Kiefer et al. [1995]. This
publication was the original description of the cloning and
sequencing of BAK1, BAK2, and BAK3. Here these authors
categorize BAK3 as a pseudogene, but indicate that BAK2 is not a
processed gene. The chromosome 20 BAK2 sequences of
AC_000152.1 and NW_00183664 contain ATG/GCT/TCG from
the DNA of Dr. J. Craig Venter [Levy et al., 2007] and so are also
from a single isolate. It is interesting to note that Venter’s DNA
sequence appears to be somewhat of an outlier when compared to
the other complete human genomes so far sequenced [Ahn et al.,
2009]. Please note that we compared our results to the reference
and not ancillary sequences, and that regardless of the sequence
variations among the BAK2 genes it is clear that the sequence we
amplified contains the sequence present in BAK1.
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Table 1. Sequence of BAK1 and BAK2 cDNA
BAK1 Amino Acid ] 21 4 5
BAK1 Nucleotide ] 217 645
BAK1 reference NM_001188 ATG/GCT/TCG CCA/GCA/TGG
AAA sample ATG/GCT/TCG CCA/GCA/TGG
AA cDNA ATG/GCT/TCG CCA/GCA/TGG
BAK2 reference NC_000020.10 ATG/GCC/TCG CCA/GCG/TGG
BAK2 NT_011362
a ATG/GCC/TCG CCA/GCG/TGG
BAK2 NG_000850.5 ATG/GCT/TCG CCA/GCG/TGG
BAK2 AC_00152.1 and NW_00183664
b ATG/GCT/TCG CCA/GCG/TGG
aThis sequence has the same citation as the reference sequence NC_000020.10
[Deloukas et al., 2001].
bBoth of these sequences are from a single isolate [Levy et al., 2007].
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results for the same BAK2 sequences and BAK1 sequence at
nucleotide 645. All the BAK2 sequences have the CCA/GCG/TGG
sequence, whereas the BAK1 sequence is CCA/GCA/TGG. All of
our samples are the same as the BAK1 sequence and contain the
sequence CCA/GCA/TGG (Table 1).
We believe that our critics have been very subjective in their use
of sequence data in that they chose not to discuss the concordance
of our results at nucleotides 217 and 645 with the BAK1 sequence,
but only to discuss the discordance at 217 in the BAK2 sequences
by relying on three variant BAK2 sequences. This would appear to
be a good example of a selective use of sequence data, so that even
though we reported on actual sequence data from individuals,
they chose to solely rely on reported data from these three cases.
Although we feel that we are clearly dealing with single
nucleotide polymorphisms (SNPs) in BAK1, as noted previously
in the original article reporting BAK2 in chromosome 20 [Keiffer
et al., 1995], the authors reported that it could not be considered a
processed gene. Finally, a recent study has identified correlation of
34 trait-associated SNPs with copy number variations, and
interestingly, one of the genes identified was BAK1 [Conrad
et al. 2010]. Although the associated trait was testicular germ cell
tumors, it suggests that BAK1 SNPs have the potential to be
disease associated.
Again, we are grateful to Ku ¨ry et al. [2010] for raising a number
of issues that are likely to be of importance as we uncover
increasing amounts of human genome variation. In particular,
their letter raises a number of key questions that are only likely to
increase in significance in the coming years. These questions
include the following:
1. What is the degree and significance of gene sequence fidelity?
Clearly, the authors of this letter have placed a great deal of
faith in the importance of gene fidelity, as they have selectively
used this principle to very rigidly separate BAK1 from BAK2
sequence data.
2. What is the importance of intraorganismal genetic hetero-
geneity? Differences between diseased, nondiseased tissues, and
blood have long been a staple of cancer research. Do they also
occur in other diseases? What are the possible effects of
intraorganismal genetic heterogeneity on the controversies
surrounding GWAS?
3. What actually are pseudogenes, how are they related to similar
regular genes and how does the discovery of some pseudogenes
being expressed [Brunson et al., 2010], affect our ideas about
their genetic significance? Can pseudogenes indeed play a role
in genetics?
4. What forms of RNA editing are possible and what might be
their significance, particularly in establishing genotype to
phenotype relationships?
Finally, The question of prematurely overrating results is clearly
a fact of life in modern science. As Ku ¨ry et al. [2010] noted, it was
not us that did so in our article, but rather the popular Scientific
Press. The fact that such behavior goes on constantly is perhaps a
measure of the importance of public relations (PR) in modern
scientific research. All large universities and research institutions
now have a PR department, whose goal is to make certain that
their research reputation is suitably promoted and enhanced. This
has lead to a veritable orgy of press releases announcing countless
major scientific breakthroughs, most of which in the harsh light of
reality tend to be highly overrated. Further, such behavior is not
just limited to the PR departments of institutions, but also the PR
departments of some of our most highly rated scientific
publications. Perhaps it is time to seriously consider the value of
such press releases, as they are in many ways resulting in
irresponsible and even poor science. This can perhaps best be
illustrated by the numerous press conferences that have
announced the results of experiments that have not yet been
completed or even undertaken! As scientist and researchers we are
constantly being reminded of the positive benefits of publicity, but
perhaps it is also time to consider the negative aspects as well.
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